| Name | Title | Contact Details |
|---|
BIOCiS is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RareCyte is a company focused on characterizing and isolating rare cells from blood.
We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.
C2N Diagnostics is a privately-held biotechnology company based in St. Louis, Missouri. We focus on the development of clinical diagnostics and therapeutics for serious brain disorders, with a particular emphasis on Alzheimer`s disease and related forms of progressive neurodegeneration.
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.